Coronavirus, vaccine candidate covaxine, Corona vaccine candidate covaxine, Vaccine manufacturer Bharat Biotech, manufacturer Bharat Biotech, Bharat Biotech

Finally, India made a coronavirus vaccine. Bharat Biotech and ICMR did wonders. Human Trials started.

# Headlines Featured Government Health Health Tops Trending World

Vaccine manufacturer Bharat Biotech announced on Monday that it has successfully developed the country’s first vaccine candidate, Covaxin. The biotech said that it has been prepared in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). Also, its human trial will this month.

The company said this in its statement “A statement issued by the company said that the SARS-COV-2 strain was isolated at NIV in Pune and transferred to Bharat Biotech. The domestic inactivated vaccine was developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment Facility located in Genome Valley, Hyderabad.”

A statement issued by the company said that the SARS-COV-2 strain was isolated at NIV in Pune and transferred to Bharat Biotech. The domestic inactivated vaccine was developed and manufactured at Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment Facility located in Genome Valley, Hyderabad.

The Drug Controller General of India, Central Drugs Standard Control Organization (CDSCO), Ministry of Health and Family Welfare have given permission to start the Phase 1 and Phase 2 human clinical trials. Prior to this, the company had submitted the results obtained from preclinical studies. Human clinical trials are scheduled to begin across India next month.

Bharat Biotech Chairman’s statement

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, said, “We are proud to announce India’s first domestically developed vaccine, Covaxin, against Covid-19. The involvement of ICMR and NIV has been instrumental in the development of this vaccine. “

He said that with the active support and guidance of CDSCO, the project was approved. Our R&D and manufacturing teams worked tirelessly towards this platform in the deployment of our own technologies.

Undergoing national regulatory protocols, the company accelerated its objective in completing comprehensive pre-clinical studies. The results of these studies have been impressive and have demonstrated extremely safe and effective immune responses.